ClinicalTrials.gg
CompletedNCT01915823Updated Jun 29, 2015Results posted

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

A Phase 3 interventional study of azelastine hydrochloride and fluticasone propionate and Dymista vehicle in Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 31 sites in United States. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2015-06-29.

Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.

Enrollment
9th of 16
348 · median 415
Started
2013
the only one that year
Phase 3
9 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
7 of 16
Meda Pharmaceuticals

Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 9 in phase 3, and was the 10th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About azelastine

azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to \<12 years old who have seasonal allergic rhinitis.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ages >4 years to \<12 years of age, inclusive at the screening visit
  • The parent/caregiver must provide written and the child must provide pediatric assent, if possible
  • Willing and able to comply with the study requirements
  • Have a history of seasonal allergic rhinitis (SAR) to pollen in the prevailing allergy season.
  • The presence of immunoglobulin E (IgE)-mediated to prevailing pollen, confirmed by a positive response to skin prick test. A histamine skin test must also be positive. A positive response for both the pollen skin test and the histamine skin test is defined as a wheal diameter of at least 4 mm larger than the negative saline control
  • General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
  • On the first day of the placebo lead-in period (Visit 1) subjects must have a 12-hour reflective total nasal symptoms score (rTNSS )of ≥6 and a reflective congestion score of ≥2 to qualify for entry.

At Visit 2:

  • Have taken at least 6 doses of the placebo lead-in medication during the placebo lead-in period
  • At Visit 2, to be eligible for entry into the double-blind treatment period, subjects must have the total of the seven lead-in symptom assessments during the past 3 days of the lead-in period including the Day of Randomization (Visit 2, Day 1):

    • a 12-hour reflective TNSS ≥ 42
    • a 12-hour reflective congestion score of ≥14

Exclusion criteria

Exclusion Criteria:

  • On nasal examination, the presence of any superficial or moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1B - 4) at either the screening visit or randomization visit
  • Nasal disease(s) likely to affect deposition of intranasal medication, such as acute or chronic sinusitis, rhinitis medicamentosa, polyposis, or clinically significant nasal structural abnormalities.
  • Nasal surgery or sinus surgery within the previous year.
  • The use of any drug within 30 days prior to signing the /pediatric assent at Visit 1. No investigational products are permitted for use during the conduct of this study
  • Presence of any to azelastine hydrochloride and/or fluticasone propionate or drugs similar to azelastine hydrochloride and/or fluticasone propionate
  • Respiratory tract infections within 14 days prior to Visit1
  • Significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
  • Chronic obstructive sleep apnea syndrome (clinical diagnosis)
  • Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug that might significantly affect the subject's ability to complete this trial
  • Clinically relevant abnormal physical findings which, in the opinion of the investigator or sponsor's medical monitor, would interfere with the objectives of the study or that may preclude compliance with the study procedures
  • Family members of the research center or private practice personnel who are directly involved in this study are excluded
  • Members of the same household cannot be enrolled at the same time
  • Subjects who have used medications or therapies that could interfere with safety and efficacy evaluations and have not had the proper washouts from these medications or therapies
  • Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism
  • Positive pregnancy test in female subjects ≥ 9 years of age
  • Females who are pregnant or nursing
  • Females of who are not abstinent and not practicing a medically acceptable method of
  • Subjects who fail to complete the symptom diary during the lead-in period, defined as missing data for >50% of entries
  • Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimens following a brief period of missed injections do not preclude participation). Dose reduction when a new bottle is used does not preclude participation.
  • Planned travel outside of the pollen area during the study period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
348 participants (actual)

Study arms

  • Active comparator
    Dymista

    (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily

    Drug: azelastine hydrochloride and fluticasone propionate

  • Placebo comparator
    Dymista vehicle

    Dose: vehicle only Regimen: 1 spray per nostril twice daily

    Drug: Dymista vehicle

Interventions

  • Drugazelastine hydrochloride and fluticasone propionate

    Drug pages: Azelastine · Fluticasone

    Also known as: Dymista

  • DrugDymista vehicle

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Primary Efficacy

    change from baseline in AM+PM rTNSS (reflective total nasal symptoms score): ITT( intent to treat population)change from baseline in 12-hour reflective total nasal symptom score (rTNSS) consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary for the entire 14 day study period.The measurement scale is 0 to 24 so that the higher the number the worse the symptom.A reduction in symptom severity score is indicated by a negative value.A greater negative value suggests improvement.

    Time frame: 15 days of treatment

Secondary outcomes

  1. Safety

    * Subject-reported adverse experiences (incidence, type, and severity of adverse events) * Nasal Examinations * Vital signs assessments

    Time frame: entire length of study (day 1 to day 22)

Other outcomes

  1. Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)

    Change from baseline to Visit 4 in the ITT ( intent to treat) Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) in subjects equal to or greater than 6 years old and less than12 years old compared to placebo.Scored on a 0 to 7 scale with 0 being not troubled at all and 7 being extremely troublesome. The higher the difference the better the result.

    Time frame: day 1 to day 15 of treatment

07

Results

Posted Jun 29, 2015

Participant flow

Participant flow — Overall Study
MilestoneDymistaDymista Vehicle
Started173175
Completed171173
Not completed22

Outcome measures

PrimaryPrimary Efficacy

change from baseline in AM+PM rTNSS (reflective total nasal symptoms score): ITT( intent to treat population)change from baseline in 12-hour reflective total nasal symptom score (rTNSS) consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary for the entire 14 day study period.The measurement scale is 0 to 24 so that the higher the number the worse the symptom.A reduction in symptom severity score is indicated by a negative value.A greater negative value suggests improvement.

Time frame:
15 days of treatment
Reported as:
Mean · units on a scale
Primary Efficacy
units on a scaleDymistaDymista Vehicle
Primary Efficacy-3.83 ± 5.154-2.77 ± 4.731
SecondarySafety

* Subject-reported adverse experiences (incidence, type, and severity of adverse events) * Nasal Examinations * Vital signs assessments

Time frame:
entire length of study (day 1 to day 22)
Reported as:
Number · occurance
Safety
occuranceDymistaDymista Vehicle
Safety2823
Other pre-specifiedPediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)

Change from baseline to Visit 4 in the ITT ( intent to treat) Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) in subjects equal to or greater than 6 years old and less than12 years old compared to placebo.Scored on a 0 to 7 scale with 0 being not troubled at all and 7 being extremely troublesome. The higher the difference the better the result.

Time frame:
day 1 to day 15 of treatment
Reported as:
Mean · units on a scale
Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)
units on a scaleDymistaDymista Vehicle
Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)-.91 ± 1.22-.66 ± 1.22

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dymista—0/173 (0%)13/173 (7.5%)
Dymista Vehicle—0/175 (0%)6/175 (3.4%)
Most frequent other events
Most frequent other events
EventDymistaDymista Vehicle
dysgusiaNervous system disorders7/1730/175
epistaxisRespiratory, thoracic and mediastinal disorders6/1736/175

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DymistaDymista VehicleTotal
<=18 years173175348
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)DymistaDymista VehicleTotal
Mean8.5 ± 2.118.4 ± 2.068.4 ± 2.08
Sex: Female, Male
Sex: Female, Male(Participants)DymistaDymista VehicleTotal
Female7785162
Male9690186
Region of Enrollment
Region of Enrollment(participants)DymistaDymista VehicleTotal
United States173175348
08

Study locations

31 sites
  • Clinical Research Center of Alabama,LLC
    Birmingham, Alabama 35209, United States
  • Little Rock Allergy and Asthma Clinical research Center
    Little Rock, Alaska 72205, United States
  • Clinical Research Atlanta
    Atlanta, Georgia 30342, United States
  • Aeroallergy Research Laboratories of Savannah
    Savannah, Georgia 31406, United States
  • Atlanta Allergy and Asthma Clinic
    Stockbridge, Georgia 30281, United States
  • Sneeze, Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Clinical Research Institute of Indiana
    Indianapolis, Indiana 46208, United States
  • Family Allergy and Asthma Reserach
    Louisville, Kentucky 40215, United States
  • Institute for Asthma and Allergy PC
    Wheaton, Maryland 20902, United States
  • Respiratory Medicine Research Institute of Michigan
    Ypsilanti, Michigan 48197, United States
  • Clinical Research Institute
    Plymouth, Minnesota 55402, United States
  • The Clinical Research Center
    St. Louis, Missouri 63141, United States
  • Clinical Research of the Ozarks,Inc
    Warrensburg, Missouri 64093, United States
  • Allergy and Asthma Research NJ inc
    Mount Laurel, New Jersey 08054, United States
  • Atlantic Research Center
    Ocean, New Jersey 07712, United States
  • Princeton Center for Clinical Research
    Skillman, New Jersey 08558, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45231, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Oklahoma Institute of Allergy and Asthma
    Oklahoma City, Oklahoma 73131, United States
  • Allergy and Asthma Specialist PC
    Blue Bell, Pennsylvania 19422, United States
  • Asthma and Allergy Research Associate
    Upland, Pennsylvania 19013, United States
  • National Allergy, Asthma and Urticaria of Charleston
    Charleston, South Carolina 29407, United States
  • Allergy and Asthma Consultants, LLP
    Charleston, South Carolina 29414, United States
  • Isis Clinical Research, LLC
    Ausitn, Texas 78731, United States
  • Sirius Clinical Research
    Austin, Texas 78759, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Live Oak Allergy and Asthma Clinic
    San Antonio, Texas 78233, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
  • Immunology/allergy and asthma Care of Waco
    Waco, Texas 76712, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013 and a primary completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2013
First posted
Aug 5, 2013
Start
Jul 2013
Primary completionActual
Feb 2014
Results first posted
Jun 29, 2015
Last update
Jun 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01915823
Responsible party
Sponsor
First posted
Aug 5, 2013
Start date
Jul 2013
Primary completion
Feb 2014
Results posted
Jun 29, 2015
Last update
Jun 29, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azelastine · Fluticasone

Start the discussion